Axplora used DCAT Week to highlight its accelerated investment in high‑potency API (HPAPI) development and manufacturing, a strategy fueled by more than €100 million in global site upgrades over the past year.
In an exclusive interview with Contract Pharma, Chief Commercial Officer Arul Ramadurai emphasized that demand for HPAPIs is soaring across oncology, immunology, and emerging modalities such as steroid conjugates, with 1,000+ highly potent molecules currently in development.
During the event, Ramadurai detailed Axplora’s three‑pillar investment focus—cycle time, yield, and asset fit—designed to accelerate tech transfer, strengthen R&D and QC capabilities, and enable efficient scale‑up.
He also underscored Axplora’s proactive global sourcing strategy, which prevented pandemic‑era supply disruptions, along with expanded ESG commitments, including alignment with SBTi and Ecovadis Gold certification at its Italian site.
